We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel 3D-Printed Technology Lowers Cost of ELISA

By LabMedica International staff writers
Posted on 06 Jun 2019
Print article
Image: The unique pipette tip created with a 3D printer to perform enzyme-linked immunosorbent assays (Photo courtesy of the University of Connecticut).
Image: The unique pipette tip created with a 3D printer to perform enzyme-linked immunosorbent assays (Photo courtesy of the University of Connecticut).
Traditional enzyme-linked immunosorbent assay (ELISA) tests are performed on plates featuring 96 micro-wells; each well works as a separate testing chamber where samples can be combined with various agents that will then react with the sample, typically by changing color.

While effective and accurate, the equipment used to run ELISA is expensive, often costing thousands of dollars to install in a laboratory, and requires specialized training to conduct testing, as improper techniques can lead to incorrect results. The agents used in the actual tests, usually various forms of antibodies, can also be expensive.

Scientists at the University of Connecticut (Storrs, CT, USA) created a novel pipette-based “ELISA in a tip” as a new versatile diagnostic tool featuring better sensitivity, shorter incubation time, accessibility, and low sample and reagent volumes compared to traditional ELISA. Capture and analysis of data by a cell phone facilitates electronic delivery of results to health care providers.

Pipette tips were designed and 3D printed as adapters to fit most commercial 50–200 μL pipettes. Capture antibodies (Ab1) are immobilized on the inner walls of the pipette tip, which serves as the assay compartment where samples and reagents are moved in and out by pipetting. Signals are generated using colorimetric or chemiluminescent (CL) reagents and can be quantified using a cell phone, CCD camera, or plate reader.

Traditional ELISA plate micro-wells hold 400 µL of fluids each, but the reactions needed to measure test results only occur on the plastic walls of the well. While the 3D-printed ELISA tips hold only 50 µL, the design of the reservoir inside the tip dramatically increases the surface area where reactions occur, allowing the scientists to use much less of the costly antibodies used to conduct the test, and significantly reducing the time needed to process the test and read the results.

The team utilized pipet-tip ELISA to detect four cancer biomarker proteins with detection limits similar to or lower than microplate ELISAs at 25% assay cost and time. Recoveries of these proteins from spiked human serum were 85% to 115% or better, depending slightly on detection mode. Using CCD camera quantification of CL with femto-luminol reagent gave limits of detection (LOD) as low as 0.5 pg/mL. Thirteen patient samples were assayed for three biomarker proteins with results well correlated to conventional ELISA and an established microfluidic electrochemical immunoassay.

Mohamed Sharafeldin, MSc, a research assistant and first author of the study, said, “We didn't want to make a big change in the traditional ELISA; we just made engineered, controlled changes. So, the basics are the same. We use the same antibodies at the same concentrations that they use with conventional or traditional ELISA, so we are using the same protocols. Anything that can be run by normal ELISA can be run by this, with the advantage of being less expensive, much faster and accessible.” The study was published on May 3, 2019, in the journal Analytical Chemistry.

Related Links:
University of Connecticut

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Unstirred Waterbath
HumAqua 5

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more